Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy
and safety of different dose-intervals of Lanreotide Autogel 120mg according to international
standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.